imanjen13
5 minutes ago
An eventual buyout will look more realistic when the annual yearly revenue, now estimated to be 80M without Vyvanse, Percocet et al, exceed the 100M a year mark which seems possible, if not likely, in the coming fiscal year commencing in April 2025. The real kicker will include a victory in the Oxyc